NUCB2/nesfatin-1 is associated with elevated scores of anxiety in female obese patients

Psychoneuroendocrinology

Volumn 38, Issue 11, 2013, Pages 2502-2510

  Hofmann, Tobias ^a   Stengel, Andreas ^a   Ahnis, Anne ^a   Buße, Petra ^a   Elbelt, Ulf ^a   Klapp, Burghard F ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Emotion; Gut brain axis; Mood; Nucleobindin2; Psychobiology; Psychoneuroendocrine; Psychosomatic

Indexed keywords

NESFATIN 1; NUCLEOBINDIN2 PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANXIETY; ARTICLE; BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR CLINICAL STUDY; NUTRITIONAL STATUS; OBESITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SCORING SYSTEM; STRESS;

EMOTION; GUT-BRAIN-AXIS; MOOD; NUCLEOBINDIN2; PSYCHOBIOLOGY; PSYCHONEUROENDOCRINE; PSYCHOSOMATIC;

ADULT; ANXIETY DISORDERS; BODY MASS INDEX; CALCIUM-BINDING PROTEINS; DEPRESSION; DNA-BINDING PROTEINS; FEMALE; HUMANS; MIDDLE AGED; NERVE TISSUE PROTEINS; OBESITY; PSYCHIATRIC STATUS RATING SCALES; STRESS, PSYCHOLOGICAL;

EID: 84886099182     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2013.05.013     Document Type: Article

References (48)

1. Ari M., Ozturk O.H., Bez Y., Oktar S., Erduran D. High plasma nesfatin-1 level in patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:497-500.
2. Aslan M., Celik O., Celik N., Turkcuoglu I., Yilmaz E., Karaer A., Simsek Y., Celik E., Aydin S. Cord blood nesfatin-1 and apelin-36 levels in gestational diabetes mellitus. Endocrine 2012, 41:424-429.
3. Aydin S., Dag E., Ozkan Y., Erman F., Dagli A.F., Kilic N., Sahin I., Karatas F., Yoldas T., Barim A.O., Kendir Y. Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders. Mol. Cell. Biochem. 2009, 328:49-56.
4. Barry D., Pietrzak R.H., Petry N.M. Gender differences in associations between body mass index and DSM-IV mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Ann. Epidemiol. 2008, 18:458-466.
5. Baumeister H., Harter M. Mental disorders in patients with obesity in comparison with healthy probands. Int. J. Obes. (Lond.) 2007, 31:1155-1164.
6. Blaine B. Does depression cause obesity? A meta-analysis of longitudinal studies of depression and weight control. J. Health Psychol. 2008, 13:1190-1197.
7. Bloem B., Xu L., Morava E., Faludi G., Palkovits M., Roubos E.W., Kozicz T. Sex-specific differences in the dynamics of cocaine- and amphetamine-regulated transcript and nesfatin-1 expressions in the midbrain of depressed suicide victims vs. controls. Neuropharmacology 2012, 62:297-303.
8. Brailoiu G.C., Dun S.L., Brailoiu E., Inan S., Yang J., Chang J.K., Dun N.J. Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology 2007, 148:5088-5094.
9. Carlini V.P., Varas M.M., Cragnolini A.B., Schioth H.B., Scimonelli T.N., de Barioglio S.R. Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin. Biochem. Biophys. Res. Commun. 2004, 313:635-641.
10. Emmerzaal T.L., Kozicz T. Nesfatin-1; implication in stress and stress-associated anxiety and depression. Curr. Pharm. Des. 2013, http://www.ncbi.nlm.nih.gov/pubmed/23537084 (Epub ahead of print).
11. Fliege H., Rose M., Arck P., Walter O.B., Kocalevent R.D., Weber C., Klapp B.F. The Perceived Stress Questionnaire (PSQ) reconsidered: validation and reference values from different clinical and healthy adult samples. Psychosom. Med. 2005, 67:78-88.
12. Foo K.S., Brismar H., Broberger C. Distribution and neuropeptide coexistence of nucleobindin-2 mRNA/nesfatin-like immunoreactivity in the rat CNS. Neuroscience 2008, 156:563-579.
13. Gariepy G., Nitka D., Schmitz N. The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis. Int. J. Obes. (Lond.) 2010, 34:407-419.
14. Goebel M., Stengel A., Wang L., Lambrecht N.W., Taché Y. Nesfatin-1 immunoreactivity in rat brain and spinal cord autonomic nuclei. Neurosci. Lett. 2009, 452:241-246.
15. Goebel M., Stengel A., Wang L., Taché Y. Restraint stress activates nesfatin-1-immunoreactive brain nuclei in rats. Brain Res. 2009, 1300:114-124.
16. Gräfe K., Zipfel S., Herzog W., Löwe B. Screening psychischer Störungen mit dem "Gesundheitsfragebogen für Patienten (PHQ-D)". Ergebnisse der deutschen Validierungsstudie (Screening of mental disorders with the PRIME MD Patient Health Questionnaire-German version. Results of the German validation study). Diagnostica 2004, 50:171-181.
17. Groschl M., Uhr M., Kraus T. Evaluation of the comparability of commercial ghrelin assays. Clin. Chem. 2004, 50:457-458.
18. Gunay H., Tutuncu R., Aydin S., Dag E., Abasli D. Decreased plasma nesfatin-1 levels in patients with generalized anxiety disorder. Psychoneuroendocrinology 2012, 37:1949-1953.
19. Heilig M., Soderpalm B., Engel J.A., Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl.) 1989, 98:524-529.
20. Kohno D., Nakata M., Maejima Y., Shimizu H., Sedbazar U., Yoshida N., Dezaki K., Onaka T., Mori M., Yada T. Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology 2008, 149:1295-1301.
21. Konczol K., Bodnar I., Zelena D., Pinter O., Papp R.S., Palkovits M., Nagy G.M., Toth Z.E. Nesfatin-1/NUCB2 may participate in the activation of the hypothalamic-pituitary-adrenal axis in rats. Neurochem. Int. 2010, 57:189-197.
22. Lawson E.A., Miller K.K., Blum J.I., Meenaghan E., Misra M., Eddy K.T., Herzog D.B., Klibanski A. Leptin levels are associated with decreased depressive symptoms in women across the weight spectrum, independent of body fat. Clin. Endocrinol. (Oxf.) 2012, 76:520-525.
23. Levenstein S., Prantera C., Varvo V., Scribano M.L., Berto E., Luzi C., Andreoli A. Development of the Perceived Stress Questionnaire: a new tool for psychosomatic research. J. Psychosom. Res. 1993, 37:19-32.
24. Li Q.C., Wang H.Y., Chen X., Guan H.Z., Jiang Z.Y. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul. Pept. 2010, 159:72-77.
25. Liu J., Garza J.C., Bronner J., Kim C.S., Zhang W., Lu X.Y. Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine. Psychopharmacology (Berl.) 2010, 207:535-545.
26. Löwe B., Decker O., Muller S., Brahler E., Schellberg D., Herzog W., Herzberg P.Y. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med. Care 2008, 46:266-274.
27. Löwe B., Spitzer R., Zipfel S., Herzog W. Gesundheitsfragebogen für Patienten (PHQ-D). Manual und Testunterlagen. 2. Auflage (PRIME MD Patient Health Questionnaire (PHQ) - German Version. Manual and Materials, 2nd ed.) 2002, Pfizer, Karlsruhe.
28. Luppino F.S., de Wit L.M., Bouvy P.F., Stijnen T., Cuijpers P., Penninx B.W., Zitman F.G. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch. Gen. Psychiatry 2010, 67:220-229.
29. Mather A.A., Cox B.J., Enns M.W., Sareen J. Associations of obesity with psychiatric disorders and suicidal behaviors in a nationally representative sample. J. Psychosom. Res. 2009, 66:277-285.
30. Merali Z., Cayer C., Kent P., Anisman H. Nesfatin-1 increases anxiety- and fear-related behaviors in the rat. Psychopharmacology (Berl.) 2008, 201:115-123.
31. Moore M.E., Stunkard A., Srole L. Obesity, social class, and mental illness. JAMA 1962, 181:962-966.
32. Ogiso K., Asakawa A., Amitani H., Nakahara T., Ushikai M., Haruta I., Koyama K., Amitani M., Harada T., Yasuhara D., Inui A. Plasma nesfatin-1 concentrations in restricting-type anorexia nervosa. Peptides 2011, 32:150-153.
33. Oh I.S., Shimizu H., Satoh T., Okada S., Adachi S., Inoue K., Eguchi H., Yamamoto M., Imaki T., Hashimoto K., Tsuchiya T., Monden T., Horiguchi K., Yamada M., Mori M. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006, 443:709-712.
34. Okere B., Xu L., Roubos E.W., Sonetti D., Kozicz T. Restraint stress alters the secretory activity of neurons co-expressing urocortin-1, cocaine- and amphetamine-regulated transcript peptide and nesfatin-1 in the mouse Edinger-Westphal nucleus. Brain Res. 2010, 1317:92-99.
35. Ramanjaneya M., Chen J., Brown J.E., Tripathi G., Hallschmid M., Patel S., Kern W., Hillhouse E.W., Lehnert H., Tan B.K., Randeva H.S. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010, 151:3169-3180.
36. Spitzer R.L., Kroenke K., Williams J.B. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999, 282:1737-1744.
37. Spitzer R.L., Kroenke K., Williams J.B., Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch. Intern. Med. 2006, 166:1092-1097.
38. Stengel A., Goebel M., Wang L., Taché Y. Abdominal surgery activates nesfatin-1 immunoreactive brain nuclei in rats. Peptides 2010, 31:263-270.
39. Stengel A., Goebel M., Yakubov I., Wang L., Witcher D., Coskun T., Taché Y., Sachs G., Lambrecht N.W. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009, 150:232-238.
40. Stengel A., Hofmann T., Goebel-Stengel M., Lembke V., Ahnis A., Elbelt U., Lambrecht N.W., Ordemann J., Klapp B.F., Kobelt P. Ghrelin and NUCB2/nesfatin-1 are expressed in the same gastric cell and differentially correlated with body mass index in obese subjects. Histochem. Cell Biol. 2013, 139:909-918.
41. Stengel A., Taché Y. Gastric peptides and their regulation of hunger and satiety. Curr. Gastroenterol. Rep. 2012, 14:480-488.
42. Stengel A., Wang L., Taché Y. Stress-related alterations of acyl and desacyl ghrelin circulating levels: mechanisms and functional implications. Peptides 2011, 32:2208-2217.
43. Ströhle A., Holsboer F., Rupprecht R. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacology 2000, 22:251-256.
44. Tan B.K., Hallschmid M., Kern W., Lehnert H., Randeva H.S. Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. J. Clin. Endocrinol. Metab. 2011, 96:E669-E673.
45. Tsuchiya T., Shimizu H., Yamada M., Osaki A., Oh-I S., Ariyama Y., Takahashi H., Okada S., Hashimoto K., Satoh T., Kojima M., Mori M. Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin. Endocrinol. (Oxf.) 2010, 73:484-490.
46. Xu L., Bloem B., Gaszner B., Roubos E.W., Kozicz T. Stress-related changes in the activity of cocaine- and amphetamine-regulated transcript and nesfatin neurons in the midbrain non-preganglionic Edinger-Westphal nucleus in the rat. Neuroscience 2010, 170:478-488.
47. Yoshida N., Maejima Y., Sedbazar U., Ando A., Kurita H., Damdindorj B., Takano E., Gantulga D., Iwasaki Y., Kurashina T., Onaka T., Dezaki K., Nakata M., Mori M., Yada T. Stressor-responsive central nesfatin-1 activates corticotropin-releasing hormone, noradrenaline and serotonin neurons and evokes hypothalamic-pituitary-adrenal axis. Aging (Albany, NY) 2010, 2:775-784.
48. Zhang Z., Li L., Yang M., Liu H., Boden G., Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 2012, 120:91-95.